Abstract
This is the latest most up-to-date Cancer Personalized Medicine Market Report
from Select Biosciences. This report presents an up-to-date and thorough
analysis of the Cancer Personalized Medicine Marketplace based upon Select
Biosciences continuing industry coverage. Personalized Medicine, especially as
it relates to Cancer, is undergoing significant growth and this report focuses
in on the science, market/commercialization, and diagnostic/therapeutics
trends in this space.
The Cancer Personalized Medicine marketplace represents the paradigm for
personalized medicine market evolution and Select Biosciences focuses in this
report on the various commercialized cancer predictor tests, their current
status, traction in the marketplace, quantitative market opportunities, and
the factors that are driving as well as challenging the expansion of this
space.
Emerging classes of cancer biomarkers such as microRNAs and epigenetics are
also examined in this report as well as the pipeline of RNAi-therapeutics for
cancer. These biomarkers and treatment methodologies are drivers of the growth
of the cancer personalized medicine marketplace for the future and therefore
Select Biosciences provides coverage of these areas in this report-together
with market participants making an impact in these particular areas.
Personalized Medicine marketplace is part of Select Biosciences continuous
industry tracking and as part of this coverage; this report presents
comprehensively the cancer personalized medicine market landscape in terms
of:
- Cancer Diagnostic Tests on the marketplace and in development that are
developed as companion-diagnostics [coupled with a therapeutic regimen]
- Landscape of In Vitro Diagnostic Multivariate Index Assays
[IVDMIAs]-multigene predictors with prognostic/predictive value
- Key Personalized Medicine Products in the Breast Cancer, Colon Cancer,
etc. market spaces-together with the characteristics/features of These
Products-HER2, oncotype DX™, MammaPrint®, UGT1A1, K-RAS, EGFR, etc.
- Worldwide market survey completed recently-June 2008-of qualitative and
quantitative market trends/metrics in this space. Report purchasers receive
access to all the raw data from the market survey via access to secure server
from Select Biosciences as well as all the annotated/analyzed data in the
report. This highly valuable and recently collected dataset is based on an
extensive market analysis performed by Select Biosciences Industry Analyst
Team-all the raw data and analyses based on the data are presented in the
report
- Quantitative market forecast-for the year 2008 through 2011
- Comprehensive profiles of the various market participants in this space
- All report purchasers are entitled to 1 hour of free consultation with
Select Biosciences Industry Analysts
Select Biosciences also includes in this report an overview of the drug
metabolism and toxicity process, the role of specific cytochr ome P450
(CYP450) enzymes, and how these impact personalized medicine.
Furthermore, in this report are presented an overview of the FDA-regulatory
process on In Vitro Diagnostic Multivariate Index Assays (IVDMIAs), and how
this impacts the market acceptance of the various cancer personalized medicine
tests either in development or out in the market.
| 
View Cart
